Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)-Reference-Cited by-同舟云学术

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)

Published:2013-05-16 Issue:20 Volume:121 Page:4137-4141
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Shanafelt Tait D.¹,Ramsay Alan G.²,Zent Clive S.¹,Leis Jose F.³,Tun Han W.⁴,Call Timothy G.¹,LaPlant Betsy⁵,Bowen Deborah¹,Pettinger Adam⁵,Jelinek Diane F.⁶,Hanson Curtis A.⁷,Kay Neil E.¹

Affiliation:

1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;

2. Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;

3. Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ;

4. Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL; and

5. Department of Health Sciences Research,

6. Department of Immunology, and

7. Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN

Abstract

Key Points Lenalidomide consolidation repairs T-cell immune synapses in CLL patients. Lenalidomide consolidation improved the quality of response in CLL patients treated with chemoimmunotherapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/20/4137/530950/4137.pdf

Reference12 articles.

1. Cancer immunotherapy comes of age.;Mellman;Nature,2011

2. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.;Ramsay;J Clin Invest,2008

3. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.;Chanan-Khan;J Clin Oncol,2006

4. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.;Ferrajoli;Blood,2008

5. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.;Chen;J Clin Oncol,2011

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

2. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms;Frontiers in Immunology;2022-10-12

3. Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?;Hematology/Oncology Clinics of North America;2021-08

4. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword;Frontiers in Immunology;2021-01-20

5. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models;Blood Advances;2020-09-04